Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 2
2005 4
2006 6
2007 8
2008 13
2009 10
2010 12
2011 13
2012 11
2013 8
2014 13
2015 13
2016 10
2017 7
2018 13
2019 5
2020 15
2021 18
2022 21
2023 19
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
Genome-wide cell-free DNA fragmentation in patients with cancer.
Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE. Cristiano S, et al. Among authors: johansen js. Nature. 2019 Jun;570(7761):385-389. doi: 10.1038/s41586-019-1272-6. Epub 2019 May 29. Nature. 2019. PMID: 31142840 Free PMC article.
Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial.
Mikkelsen MK, Lund CM, Vinther A, Tolver A, Johansen JS, Chen I, Ragle AM, Zerahn B, Engell-Noerregaard L, Larsen FO, Theile S, Nielsen DL, Jarden M. Mikkelsen MK, et al. Among authors: johansen js. Oncologist. 2022 Feb 3;27(1):67-78. doi: 10.1002/onco.13970. Oncologist. 2022. PMID: 34498352 Free PMC article. Clinical Trial.
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer.
Nimgaonkar V, Krishna V, Krishna V, Tiu E, Joshi A, Vrabac D, Bhambhvani H, Smith K, Johansen JS, Makawita S, Musher B, Mehta A, Hendifar A, Wainberg Z, Sohal D, Fountzilas C, Singhi A, Rajpurkar P, Collisson EA. Nimgaonkar V, et al. Among authors: johansen js. Cell Rep Med. 2023 Apr 18;4(4):101013. doi: 10.1016/j.xcrm.2023.101013. Epub 2023 Apr 11. Cell Rep Med. 2023. PMID: 37044094 Free PMC article.
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Chen IM, et al. Among authors: johansen js. Eur J Cancer. 2023 Feb;180:125-133. doi: 10.1016/j.ejca.2022.11.035. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592507 Free article. Clinical Trial.
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG, Boysen AK, Pallisgård N, Johansen JS, Tabernero J, Sørensen MM, Jensen BV, Hansen TF, Sefrioui D, Andersen RF, Brandslund I, Jakobsen A. Spindler KG, et al. Among authors: johansen js. Oncologist. 2017 Sep;22(9):1049-1055. doi: 10.1634/theoncologist.2016-0178. Epub 2017 Aug 4. Oncologist. 2017. PMID: 28778958 Free PMC article. Review.
Plasma YKL-40: a potential new cancer biomarker?
Johansen JS, Schultz NA, Jensen BV. Johansen JS, et al. Future Oncol. 2009 Sep;5(7):1065-82. doi: 10.2217/fon.09.66. Future Oncol. 2009. PMID: 19792974 Review.
Is YKL-40 a new therapeutic target in cancer?
Johansen JS, Jensen BV, Roslind A, Price PA. Johansen JS, et al. Expert Opin Ther Targets. 2007 Feb;11(2):219-34. doi: 10.1517/14728222.11.2.219. Expert Opin Ther Targets. 2007. PMID: 17227236 Review.
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB, Nielsen OH, Jacobsen S, Riis LB, Theile S, Bjerrum JT, Vilmann P, Johansen JS, Boisen MK, Eefsen RHL, Marie Svane I, Nielsen DL, Chen IM. Holmstroem RB, et al. J Immunother Cancer. 2022 Sep;10(9):e005111. doi: 10.1136/jitc-2022-005111. J Immunother Cancer. 2022. PMID: 36096534 Free PMC article. Clinical Trial.
201 results